Busulfan FDA Link

An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

Also Known As:

Busulfex; Myleran; Busulfan Wellcome; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Glyzophrol; Myelosan; Mylecytan; Myléran; Orphan Brand of Busulfan; Wellcome Brand of Busulfan; n-Butane-1,3-di(methylsulfonate); Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome Brand; Wellcome, Busulfan; Busulphan; 1,4-Butanediol, dimethanesulfonate

Pharmalogical Action Categories:

Alkylating Agents
Antineoplastic Agents, Alkylating
Immunosuppressive Agents
Myeloablative Agonists

Organic Chemicals: 58
- Hydrocarbons: 412
  - Acyclic Hydrocarbons
    - Alkanes: 64
      - Alkanesulfonic Acids
        Alkanesulfonates: 7
        Mesylates: 416
        Busulfan: 1454
- Alcohols: 387
  - Glycols: 31
    - Butylene Glycols: 2
      - Busulfan: 1454
- Sulfur Compounds: 135
  - Sulfur Acids
    - Sulfonic Acids: 3
      - Alkanesulfonic Acids
        Alkanesulfonates: 7
        Mesylates: 416
        Busulfan: 1454

Create Custom RSS News Feed:
	Busulfan (Busulfex)
	Nicardipine (Dagan)

Pdl Biopharma Inc Product Research

Products